Completed Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) NCT03213665 Conditions Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, +91 more Locations Children's Hospital of Alabama — Birmingham, Alabama, United States Providence Alaska Medical Center — Anchorage, Alaska, United States Banner Children's at Desert — Mesa, Arizona, United States Phoenix Childrens Hospital — Phoenix, Arizona, United States View all 117 locations View more locations Show fewer locations Loading locations... View Trial Details
